Evidence map›Paper›PMID 33561079›Full record

ReviewJournal of clinical medicine2021

Pharmacogenomic Biomarkers of Follicle-Stimulating Hormone Receptor Malfunction in Females with Impaired Ovarian Response-A Genetic Survey.

Alireza Tafazoli, Sławomir Wołczyński, Natalia Wawrusiewicz-Kurylonek, Seyed-Alireza Esmaeili, Wojciech Miltyk

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Effects ofFrontiers in endocrinology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Alireza TafazoliDepartment of Analysis and Bioanalysis of Medicines, Faculty of Pharmacy with the Division of Laboratory Medicine, Medical University of Białystok, 15-089 Białystok, Poland.ORCID 0000-0002-0344-9941
Sławomir WołczyńskiDepartment of Reproduction and Gynecological Endocrinology, Medical University of Białystok, 15-222 Białystok, Poland.
Natalia Wawrusiewicz-KurylonekDepartment of Clinical Genetics, Medical University of Białystok, 15-089 Białystok, Poland.
Seyed-Alireza EsmaeiliImmunology Department, Faculty of Medicine, Mashhad University of Medical Sciences, 9177948564 Mashhad, Iran.
Wojciech MiltykDepartment of Analysis and Bioanalysis of Medicines, Faculty of Pharmacy with the Division of Laboratory Medicine, Medical University of Białystok, 15-089 Białystok, Poland.ORCID 0000-0001-5150-6093
Medical University of Białystok · PLMashhad University of Medical Sciences · IR

Funding

Horizon 2020 Framework Programme 754432
6 · The paper itself

Abstract

Follicle-stimulating hormone receptor (FSHR) plays an essential role as one of the most important molecules in response to some of infertility related medications. Impaired ovarian reserve and poor response to such treatments are partially dependent on the FSHR molecule itself. However, the function and drug sensitivity for this receptor may change due to various allele and polymorphisms in the

Indexed as

FSHRpersonalized drug therapypharmacogenomics

Identifiers

PMID33561079
PMCPMC7825139
OpenAlexW3118874968

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.